


Harvard Chinese Life Science Annual Research Symposium 2013

April 13-14, 2013

Folkman Auditorium, Enders Building
Boston Children's Hospital & Harvard Medical School
300 Longwood Ave, Boston, MA 02115

Transforming Medicine through Innovative Integration



Harvard Medical School
Chinese Scientists and Scholars Association
(HMS-CSSA)
Harvard School of Public Health
Chinese Students and Scholars Association
(HSPH-CSSA)

Organizing Committee Advisors

Biomedical Research

<p>Dr. Xi He, Professor Children's Hospital Boston Harvard Medical School</p>	<p>Dr. Keji Zhao, Professor National Heart Lung and Blood Institute</p>	<p>Dr. Yi Zhang, Professor Children's Hospital Boston Harvard Medical School Howard Hughes Medical Institute</p>
<p>Dr. Xiaole (Shirley) Liu, Professor Dana-Farber Cancer Institute Harvard Medical School Harvard School of Public Health</p>	<p>Dr. Jianzhu Chen, Professor Massachusetts Institute of Technology</p>	

Translational Medicine

<p>Dr. Jiping Wang, Professor Brigham and Women's Hospital Harvard Medical School</p>	<p>Dr. Winston Patrick Kuo, Professor Harvard Catalyst – LITT Harvard Medical School Harvard Dental School</p>	<p>Dr. Jing Ma, Professor Brigham and Women's Hospital Harvard Medical School</p>
--	---	--

Bio-Pharmaceutical Industry

<p>Dr. Yuanli Liu Director of the HSPH China Initiative Harvard School of Public Health</p>	<p>Dr. Bai Lu Vice President of Biology R&D center (Shanghai), GlaxoSmithKline</p>	<p>Dr. Yuelei Shen President &CEO at Biocytogen</p>
--	---	--

Organizing Committee

Harvard Medical School Chinese Scientists and Scholars Association (HMS-CSSA)

Chaoshe Guo; Wei Song; Sui Wang; Jing Wang; Yifan Lu; Ming Liu; Jin Zhang; Dongpo Cai; Hai Hu; Dan Tong; James Chen; Wenjia You; Ting Feng; Yilai Shu; Xiaofeng Wang; Shubai Liu; Wenyu Song; Qiming Sun; Xiaohui Han; Hongliang Ren

Harvard School of Public Health Chinese Students and Scholars Association (HSPH-CSSA)

Mu Chen; Shangzhi Gao; Xindi Hu; Tian Chu; Zhaozhong Zhu

Agenda

April 13, Saturday

8:45 am – 9:15 am	Registration and Light refreshment
Session 1. Biomedical Research	
9:30 am – 10:00 am	<p>Opening Remark (Host: Dr. Xi He) Dr. William W. Chin Executive Dean for Research, Harvard Medical School</p>
<p>Epigenetics and Related Diseases (Host: Dr. Xiaole Shirley Liu)</p>	
10:00 am – 10:30 am	<p>Mechanism and function of Tet-mediated 5mC oxidation Dr. Yi Zhang Professor, Children’s Hospital Boston, Harvard Medical School Howard Hughes Medical Institute</p>
10:30 am – 11:00 am	<p>Dr. Xihong Lin Professor, Department of Biostatistics, Harvard School of Public Health</p>
11:00 am – 11:20 am	Tea Break
11:20 am – 11:50 am	<p>Histone variant H2A.Z sets the stage for ESC differentiation Dr. Keji Zhao Director of the Systems Biology Center at the National Heart, Lung, and Blood Institute (NHLBI)</p>
11:50 am -12:05 pm	<p>Tet family of 5mC hydroxylases Play Critical Roles in Eye and Neural Development and Human Cancer Dr. Yufei Xu (Postdoc Award Recipient) Brigham and Women’s Hospital</p>

12: 05pm – 12:10 pm	Postdoc Award
<p>Lunch</p> <p>Technology Innovation (Host: Dr. Yi Zhang)</p>	
1:30 pm – 2:00 pm	<p>Neuroengineering: Molecular and Optical Axes of Control</p> <p>Dr. Feng Zhang Assistant Professor, Departments of Brain and Cognitive Sciences and Biological Engineering. MIT Broad Institute of MIT and Harvard</p>
2:00 pm – 2:30 pm	<p>Manipulation of memory engrams</p> <p>Dr. Xu Liu Research Scientist, the Picower Institute for Learning and Memory, MIT</p>
2:30 pm – 2:45 pm	<p>Systematic Identification of Synergistic Drug Pairs Targeting HIV</p> <p>Dr. Xu Tan (Postdoc Award Recipient) Brigham and Women's Hospital</p>
2:45 pm – 3:00 pm	<p>Journey to Tumor Targeting: Engineering of Biodegradable Nanoparticles for Cancer Therapy</p> <p>Dr. Zeyu Xiao (Postdoc Award Recipient) Brigham and Women's Hospital</p>
3:00 pm – 3:05 pm	Postdoc Award
3:05 pm – 3:30 pm	Tea Break
<p>Cancer and Immunology (Host: Dr. Keji Zhao)</p>	
3:30 pm – 4:00 pm	<p>The danger from within: innate immune sensing and signaling of cytosolic DNA and RNA</p> <p>Dr. Zhijian (James) Chen</p>

	<p>Professor, Department of Molecular Biology, UT Southwestern Medical Center Howard Hughes Medical Institute</p>
4:00 pm – 4:30 pm	<p>Regulation of Actin Dynamics Reactive Oxygen Species-Induced Actin Glutathionylation in Neutrophils</p> <p>Dr. Hongbo Luo Associate Professor, Boston Children’s Hospital & Harvard Medical School</p>
4:30 pm – 4:45 pm	<p>Postdoc Award Recipient Dr. Xiaodong Jiang Harvard Medical School</p>
4: 45 pm – 5:00 pm	<p>Tissue-resident macrophages keep autoimmunity in check</p> <p>Dr. Wenxian Fu (Postdoc Award Recipient) Harvard Medical School</p>
5:00pm – 5:05 pm	<p>Postdoc Award</p>
6:00 pm – 9:00 pm	<p>Reception (invited only)</p>

April 14, Sunday

Session 2. Translational Medicine (Host: Dr. Jiping Wang)	
10:00 am - 10:30 am	Mouse Models in Lung Cancer Dr. Kwok-Kin Wong Associate Professor Dana-Farber Cancer Institute Scientific Director of The Belfer Institute for Applied Cancer Science
10:30 am - 11:00 am	Closing the gap on orofacial cleft: convergence and extension in palatogenesis Dr. Chienwei (Eric) Liao Assistant Professor in Surgery at HMS; The MGH Site Director for the Harvard Plastic Surgery Residency; the Center for Regenerative Medicine and the Harvard Stem Cell Institute
11:00 am - 11:15am	Postdoc Award Recipient Dr. Xiaoyun Liao Dana-Farber Cancer Institute
11:15 am -11:30 am	Gene-Environment Interactions and Obesity Dr. Qibin Qi (Postdoc Award Recipient) Harvard School of Public Health
11:30 am - 11:35 am	Postdoc Award
11:35 pm - 12:50 pm	Lunch

Session 3. Bio-Pharmaceutical Industry	
Pharmaceuticals (Host: Dr. Yuelei Shen)	
12:50 pm – 1:20 pm	Dr. Chiang Li

	President and founder of Boston Biomedicals
1:20 pm – 1:50 pm	<p>Heal, Feed, Fuel and Secure the world - The power of Next Gen Sequencing</p> <p>Dr. Devin Dressman Associate Director of Laboratory Development and Production for Enterprise at Life Technologies</p>
<p>BioTech and Venture Capital (Host: Dr. Winston Patrick Kuo)</p>	
1:50 pm – 2:20 pm	<p>Genetically Modified Animal Model business in China: Today and Tomorrow</p> <p>Dr. Yuelel Shen Founder and CEO of Biocytogen</p>
2:20 pm – 2:50 pm	<p>Building Drug Discovery & Development Engines within the Academic Environment</p> <p>Dr. Wei Zhang Director of Commercial Strategies of HSCI</p>
2:50 pm – 3:20 pm	<p>Opportunities and challenges in China life sciences industry</p> <p>Dr. Jimmy Wei Venture Partner of KPCB China</p>
3: 20 pm – 3:40 pm	Tea Break
3:40 pm -4:10 pm	<p>From scientist to entrepreneur</p> <p>Dr. Steve Sun President and CEO of GENEWIZ</p>
4:10 pm -4:40 pm	<p>Oligonucleotides in Research and Industry</p> <p>Dr. Keyong Zou President, Boston Open Labs</p>
<p>Entrepreneurship - Panel Discussion (Moderator: Dr. Steve Sun)</p>	
4: 40 pm -5: 40 pm	Dr. Chiang Li, Dr. Yuelel Shen, Dr. Steve Sun, Dr. Wei Zhang, Dr. Jimmy Wei, Dr. Keyong Zou

--	--

Speakers



William W. Chin, M.D.
Executive Dean for Research
Bertarelli Professor of Translational Medical Science
Harvard Medical School

William W. Chin is the Executive Dean for Research, Bertarelli Professor of Translational Medical Science, and Professor of Medicine at Harvard Medical School (HMS). In the latter roles, Dr. Chin simultaneously spearheads multiple efforts to design and implement the vision for research at HMS, with special emphasis on interdisciplinary and translational research that crosses departmental and institutional boundaries.

Dr. Chin is a HMS trained endocrinologist and longstanding faculty member. His impressive career is exemplified in part by his extensive bibliography of nearly 300 papers, chapters and books, most of which were generated during his 25 years on the HMS faculty. During his tenure as a faculty member in the Department of Medicine at Brigham and Women's Hospital, Dr. Chin became chief of the Genetics Division and a Howard Hughes Medical Institute investigator, advancing to professor of Medicine, and Obstetrics, Gynecology and Reproductive Biology at HMS. As a pioneering molecular endocrinologist at HMS, Dr. Chin embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. His investigations often demonstrated a translational research theme, connecting basic laboratory discoveries to their physiologic relevance in animal models and humans.

Dr. Chin has been honored with numerous awards for research, mentorship and leadership. He is a graduate of Columbia College and Harvard Medical School. Prior to HMS, Dr. Chin was at Eli Lilly and Company, where he had worked for the last decade, most recently as senior vice president for Discovery Research and Clinical Investigation.



Yi Zhang, Ph.D.
HHMI Investigator, Senior Investigator of the Program of Cellular & Molecular Medicine of the Boston Children's Hospital, Fred Rosen chair Professor of the Department of Genetics and Department of Pediatrics of the Harvard Medical School

Dr. Yi Zhang is currently an Investigator of the Howard Hughes Medical Institute and a Senior Investigator of the Program of Cellular & Molecular Medicine of the Boston Children's Hospital. He is also a Fred Rosen chair Professor of the Department of Genetics and Department of Pediatrics of the Harvard Medical School. Before he moved to Harvard, he was a Kenan Distinguished Professor at University of North Carolina at Chapel Hill. His major interest is to understand the epigenetic mechanism of gene expression in the context of early development, stem cell reprogramming, differentiation, and reward-related

learning and memory. He is also interested in how dysregulation of chromatin modifying enzymes contribute to various human diseases, such as cancer, diabetes, and drug addiction. His group is responsible for the identification and characterization of several classes of epigenetic enzymes that include: 1) histone methyltransferases, such as PRC2 and DOT1L; 2) the JmjC family of histone demethylases; 3) the H2A ubiquitin E3 ligase PRC1; and 4) the family of Tet dioxygenases. Please visit his lab web site for more information:

<http://labs.idi.harvard.edu/zhang/lab.htm>



Xihong Lin, PhD
Professor of Biostatistics, Co-ordinating Director, Program in Quantitative Genomics, Harvard School of Public Health.

Dr. Lin Xihong received her PhD from University of Washington in 1994, B.S. in Applied Mathematics from Tsinghua University in 1989. She is the leading statistician in the world and received numerous prestigious awards and honors. She received the COPSS Presidents' Award for outstanding statistician in 2006 which is regarded as the "Nobel Prize" in statistics, the Mortimer Spiegelman Award for the Outstanding Biostatistician by American

Public Health Association, the Janet L. Norwood Award for Outstanding Achievement of a Woman in Statistics, the Mentoring Award from Harvard School of Public Health, etc. She is an elected Fellow of the American Statistical Association and Institute of Mathematical Statistics. She served as the Chair of Committee of the Presidents of Statistical Societies, 2010-2012. She is also the founding co-editor of *Statistics in Biosciences*, as well as an editor or associate editor of top journals in biostatistics and statistics.



Keji Zhao, PhD
Director of the Systems Biology Center at the National Heart, Lung, and Blood Institute


Keji Zhao, Ph.D., is director of the Systems Biology Center at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). Dr. Zhao joined the NHLBI in 1999 and was appointed a senior investigator in 2007.

Dr. Zhao's research focuses on the epigenetic regulation of chromatin, the combination of tightly-wound DNA and proteins that make up our chromosomes. Through various chemical modifications to DNA and chromatin proteins called histones, epigenetic mechanisms regulate which genes are turned on or off in a given cell, thus determining cell identity. Understanding how these epigenetic patterns are established during development and how improper epigenetic signals contribute to disease is the long-term goal for his lab.

Using advanced genome-wide mapping approaches developed at the NHLBI, Dr. Zhao's group has been pioneering whole-genome analyses of human chromatin modifications. His group was the first to map the global methylation and acetylation patterns in human histone proteins, as well as the first to provide a genome-wide map of nucleosome positioning within chromatin (nucleosomes are the core repeating unit of chromatin).

His research efforts also focus on the enzymes responsible for generating the epigenetic modifications on chromatin. Recently, his group mapped the distribution of histone acetyltransferases (HATs) and deacetylases (HDACs), enzymes that regulate histone acetylation, in human T cells. By identifying these genome-wide epigenetic patterns, Dr. Zhao's research has revealed numerous insights into the relationship between the epigenome, chromatin-modifying enzymes, and gene expression.

Dr. Zhao received his undergraduate degree from Changwei Normal College in Weifang, China in 1980 and his Doctor of Philosophy from the University of Geneva, Switzerland in 1996. Prior to joining the NHLBI, Dr. Zhao was a Damon Runyon-Walter Winchel Cancer Research Postdoctoral Fellow at Stanford University, Calif.



Zhijian (James) Chen, PhD
HHMI Investigator, Professor, University of Texas Southwestern Medical Center

Dr. Zhijian 'James' Chen is an Investigator of the Howard Hughes Medical Institute and the George L. MacGregor Distinguished Chair in Biomedical Science at UT Southwestern Medical Center. He is also an elected fellow at the American Association for the Advancement of Science. Dr. Chen received his PhD degree from SUNY-Buffalo and continued a postdoctoral training at the Salk Institute. Before moving to UT Southwestern, Dr. Chen worked at the ProScript Incorporation as a senior scientist. Dr. Chen's major research interest is to understand the function of ubiquitin-proteasome pathway, NF-kappaB and RIG-1 signaling pathways in innate immune response.




Hongbo Luo, PhD
Associate Professor, Children's Hospital Boston & Harvard Medical School

Dr. Hongbo Luo is an Associate Professor of Pathology at the Harvard Medical School and a Staff Scientist at the Boston Children's Hospital. He obtained his PhD degree at the Brandeis University and continued a postdoctoral training at the Johns Hopkins Medical School. Dr. Luo's research is focused on studying signal transduction pathways mediating various neutrophil functions.

Dr. Luo's laboratory studies signal transduction pathways mediating a variety of neutrophil functions. The laboratory uses molecular, cellular, biochemical, and chemical genetic approaches as well as animal inflammation models to dissect these pathways. The ultimate goal is to develop more efficient and effective therapies to modulate neutrophil functions in various infectious and inflammatory diseases. His training and experience in molecular biology, cell biology, and immunology have prepared him to lead the proposed project. His graduate research was carried out in the lab of Melissa Moore, at the time an HHMI investigator at Brandeis University (recently moved to University of Massachusetts Medical School), where I studied molecular mechanisms of pre-mRNA splicing and received rigorous training in biochemistry and molecular biology. As a postdoctoral fellow with Solomon Snyder at Johns

Hopkins University, He worked on an interesting family of signal molecules, inositol phosphates. His pioneering studies established a role for inositol phosphates in PtdIns(3,4,5)P₃-mediated chemotactic signal transduction pathways and provide a novel mode of regulation for PtdIns(3,4,5) P₃ signaling. The objective of the proposed research is to elucidate the role of reactive oxygen species (ROS)-induced actin glutathionylation in controlling actin dynamics in neutrophils. This research program stems from his recent finding that NADPH oxidase-dependent ROS act as key regulators of neutrophil chemotaxis. He hypothesized that ROS control actin dynamic in neutrophils via directly modulating actin glutathionylation. Relevant to this application he has established various assays to analyze neutrophil functions (e.g. time-lapse recording of migrating neutrophils, intravital microscopy to visualize neutrophil trafficking in vivo, neutrophil adoptive transfer, and detection of actin glutathionylation).



Xu Liu, PhD
Research Scientist at MIT

Dr. Xu Liu received his Ph. D. from Baylor College of Medicine at Houston, Texas in 2008. After graduation, he joined Dr. Susumu Tonegawa's lab here at MIT. Currently he is a research scientist there. He developed a system where one can label and control the expression of a particular memory using optogenetics methods. This study raised great interest in both the academia and general public. His paper became the top 10 most downloaded articles in Nature during the month of its publication and this study is widely covered by media world-wide, such as The Boston Globe, Scientific American, French journal Science & Vie, British journals Daily Mail and The Guardian. Today he will tell us this story and the new progress he made recently.



Kwok-Kin Wong, MD, PhD
Associate Professor of Medicine at Dana-Farber Cancer Institute/Harvard Medical School and Scientific Director of The Belfer Institute for Applied Cancer Science

Kwok-Kin Wong, MD, PhD, is an Associate Professor of Medicine at Dana-Farber Cancer Institute/Harvard Medical School and Scientific Director of The Belfer Institute for Applied Cancer Science. Dr. Wong's research activities focus on understanding the pathogenesis and genetic alterations involved in lung tumorigenesis, as well as testing novel lung cancer therapeutics in vivo. Toward this goal, Dr. Wong's laboratory has generated multiple genetically engineered inducible mouse models of lung cancers based on recently discovered lung cancer relevant oncogenic mutations. These models have proved invaluable for understanding the molecular mechanisms of lung cancer initiation and progression, as well as for novel targeted therapeutic testings.

Dr. Wong was elected to the American Society of Clinical Investigation in 2007. He is a recipient of the Sidney Kimmel Foundation Scholar Award and the Tisch Foundation Solid Tumor Scholar Award. He was also the recipient of the Team Science Award from the American Association for Cancer Research in 2010.

After earning his MD and PhD from the College of Physicians and Surgeons at Columbia University, Dr. Wong completed his internship and residency in Medicine at Massachusetts

General Hospital. He subsequently completed fellowship training in the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in Medical Oncology in 2001.



Eric C. Liao, MD, PhD, FACS
Assistant Professor in Surgery at HMS;
The MGH Site Director for the Harvard Plastic Surgery Residency;
the Center for Regenerative Medicine and the Harvard Stem Cell
Institute

Dr. Eric C. Liao is an Assistant Professor of Surgery at Massachusetts General Hospital, with joint Faculty appointments in the Center for Regenerative Medicine and **Error! Reference source not found.** Dr. Liao is a reconstructive plastic surgeon with expertise in microsurgery and tissue transfer. Dr. Liao also directs basic research in craniofacial genetics. Dr. Liao also serves as the residency program site director at MGH, and lectures at various courses at Harvard Medical School and Harvard College. Dr. Liao is a problem solver, whether in technical surgery, basic science, or teaching.

Dr. Liao is a graduate of Stanford University (B.S., M.S.) and received M.D. and Ph.D. degrees from Harvard Medical School and Massachusetts Institute of Technology. Dr. Liao trained in Plastic and Reconstructive surgery at Massachusetts General Hospital. He performed doctoral research with Len Zon (Children's Hospital / HHMI) investigating stem cell biology in the zebrafish model, which he now applies toward understanding the genetic basis of craniofacial development and malformations. As a plastic surgeon, Dr. Liao is a clinical tissue engineer, and has been collaborating with other CRM researchers to develop novel engineered constructs for reconstructive applications.

Dr. Liao's clinical and academic excellence has earned numerous prestigious national awards, such as the American Surgical Association Fellowship and the Basil O'Connor Scholar Award from the March of Dimes. Dr. Liao is dedicated to improving patient care through basic research, clinical investigation and teaching, with a unified aim to harness the power of regeneration toward clinical innovation.



WEI ZHANG, PhD
Director of Commercial Strategies at Harvard Stem Cell Institute

Dr. Wei Zhang's responsibilities include managing the HSCI Translational Program and incubating scientific discoveries within the broader Harvard community towards therapeutics discovery & development and commercialization. Previously, she was Corporate Vice President of Strategy and Corporate Development at Millipore Corporation, a \$1.6 billion life sciences tools company acquired by Merck KGaA. She is the Founder and President of Harvard Square Consulting, a boutique management consulting firm. Wei also spent six years with McKinsey & Company, in its Los Angeles, Boston, Shanghai, and Singapore Offices.

Dr. Zhang's work has been focused on the broader healthcare and life sciences industry on strategic, financial, and operational priorities. In addition to operating companies, she worked

extensively with PE, VC, and asset management companies on investment issues and on building portfolio companies. She has served as advisors to startup and pre-startup teams. She received her postdoctoral training at Stanford Medical School. While at Stanford, she co-founded CNetWork, a non-profit organization providing services to Asian communities in the Bay Area. She holds a Ph.D. in Immunology from Harvard University and a B.S. in Biochemistry from Peking University.



Dr. Chiang Li, PhD
President and founder of Boston Biomedicals

Dr. Chiang J. Li, Ph.D., M.D serves as the Chief Executive Officer and Chief Medical Officer at Boston Biomedical, Inc. (BBI). Dr. Li serves as an Executive Officer of Dainippon Sumitomo Pharma Co., Ltd. He is a Founder of Cequent Pharmaceuticals, Inc. He serves as Head of Global Oncology at the DSP Group. Dr. Li served as Chief Scientific Officer of Boston Biomedical, Inc. He served as the Scientific Advisor of Marina Biotech, Inc. Dr. Li established ArQule's R&D unit (ArQule Biomedical Institute), which led to the transformation of ArQule from a world leading chemistry service business to a R&D focused company. Dr. Li served as Chief Scientific Officer and Executive Vice President and Head of ArQel Biomedical Institute of ArQule Inc. from October 1, 2003 to January 26, 2007, its Senior Vice President until January 26, 2007 and Vice President since October 1, 2003. Dr. Li has pioneered the concept of, and has directed research efforts on, Activated Checkpoint Therapy(TM), the scientific basis of ArQule's oncology portfolio. Dr. Li joined ArQule in September 2003. He was a scientific founder and served as Vice President of Research of Cyclis Pharmaceuticals Inc. His research team at Harvard invented transkingdom RNAi technology, which promises to accelerate biomedical research and medical therapies based on RNA interference. As part of his commitment to ArQule, Dr. Li is on extended leave of absence from his adjunct faculty position at Harvard Medical School and from his attending Physician and the Head of a GI Cancer Laboratory at the Beth Israel Deaconess Medical Center. He serves as Chairman of Scientific Advisory Board at Cequent Pharmaceuticals, Inc. He has been the Chairman of Scientific Advisory Board and Member of Scientific Advisory Board of ArQule Inc. since January 1, 2007. He served as Chairman of Boston Biomedical, Inc. He has been Director of Cequent Pharmaceuticals Inc. since November 2006. He served as a Director of Marina Biotech Inc. from July 21, 2010 to July 14, 2011. Dr. Li conducted cancer research with Professor Arthur B. Pardee at Dana-Farber Cancer Institute, and established a productive cancer research laboratory at the Beth Israel Deaconess Medical Center, Harvard Medical School, where he serves as its Adjunct Faculty Member. He is a recipient of a number of awards and recognitions, and has published numerous highly cited articles in top leading science journals. He has published a number of highly cited articles in over 50 publications including a number of highly cited articles in top journals and holds 30 issued or filed patents. He is a Diplomate of the American Board of Internal Medicine Chairman of the Board. Dr. Li graduated from the Harvard-MIT Division of Health Science and Technology, received M.D. magna cum laude from Harvard Medical School and completed clinical residency and fellowship at Brigham & Women's hospital, Dana-Farber Cancer Institute, and Beth Israel Deaconess Medical center.



Yuelei Shen, PhD
Founder and CEO of Biocytogen

Dr. Yuelei Shen received his PhD at University of Massachusetts Medical School in 2003. His post-doctorate work was performed at Howard Hughes Medical Institute/New York University School of Medicine (2003-2008). As a postdoc fellow, Dr. Shen's work had focused on generating gene-targeting mouse models, and studied various autoimmune diseases, including EAE, asthma, colitis, and arthritis, and other autoimmune diseases. In June 2008, Dr. Shen set up Biocytogen, a biotech company committed to generating novel gene modified mouse models used for basic immunology studies and drug screening/validation. In Nov 2009, Dr. Shen initiated Biocytogen Beijing (北京百奥赛图基因生物技术有限公司) in China. From April 2011, Biocytogen started to provide mouse gene-targeting CRO services to customers from China and western countries.



Devin Dressman, PhD
Associate Director of Laboratory Development and Production for Enterprise

Dr. Devin Dressman received his PhD at University of Pittsburgh School of Medicine. During his postdoctoral research in Johns Hopkins Medical Institute, he helped invented new diagnostic tools for Cancer detection. In Ion Torrent he led the Systems Integration team in Product Development as a Senior Staff Scientist. In this roll he collaborated with all aspects of the Ion Torrent platform from Bioinformatics to Chip development to create viable products that could be released to our customers. Now Dr. Dessman is an associate Director, Laboratory Development and Production, Enterprise Solutions, Life Technologies and led the planning and execution of the laboratory arm for the Enterprise Solutions group at Life Technologies. This includes managing and leading a local laboratory group as well as planning all logistics for all of the clients.



Steve Z. Sun, Ph.D.
President and CEO of GENEWIZ

Dr. Sun is the Chairman and CEO of GENEWIZ, Inc., the company he co-founded in 1999. GENEWIZ is a contract research company that specializes in genomics services including DNA sequencing, gene synthesis, translational genomics, molecular biology, and GLP/GMP standard genomics services. GENEWIZ has established a global network of laboratory operations in New Jersey, Maryland, North Carolina, Massachusetts, Washington and California in the US, and Beijing and Suzhou in China. Dr. Sun obtained his Bachelor and Master degrees from Tsinghua University in Beijing. He obtained his Ph.D. from Columbia University in the City of New York.

Dr. Sun received his postdoctoral training at The Rockefeller University. Starting GENEWIZ, Inc. is his first job.

Dr. Sun serves as a member of the Board of Directors at Frontage Laboratories since its founding in 2000, the Innovation Sounding Board of Rutgers University's Center for Innovative Ventures of Emerging Technologies (CIVET), and the Advisory Board of the Commercialization Center of Innovative Technology (CCIT), a New Jersey (State) Economic Development Authority (NJEDA) organization.

Dr. Sun received the Ernst & Young 2010 Entrepreneur of the Year Award in New Jersey. The Ernst & Young award recognizes outstanding entrepreneurs who are building and leading dynamic and growing businesses.

GENEWIZ was named as the Business of the Year (2011) in the 100+ Employees category by NJBIZ, and received an Award for Excellence in the business expansion category from the New Jersey Business Industry (NJBIA) in 2011. GENEWIZ was ranked 28th amongst New Jersey's 50 Fastest Growing Companies by NJBIZ in 2011. Independent marketing researching firm Frost & Sullivan selected GENEWIZ, Inc. as the recipient of the Growth Strategy Leadership Award, in recognition of its high quality services and unparalleled support in the North American DNA sequencing services markets.



Jimmy Wei, PhD
Venture Partner of KPCB China

Jimmy Wei joined KPCB China as a Venture Partner in April, 2012. His primary interests are building new companies in the area of life sciences in China.

Prior to join KPCB, Jimmy was the Senior Vice President and head of business development at Hutchison MediPharma, where he led the effort to set up multiple partnerships with US and European pharmaceutical companies. Before joining Hutchison in 2007, Jimmy was the Deputy General Manager of Burrill China Group, where he managed Burrill's business activities related to the Greater China region. Prior to Burrill, Jimmy was the Vice President for WI Harper Group to oversee firm's life sciences investment. He also worked for McKinsey Shanghai office as a management consultant. Prior to the business career, Jimmy has conducted R&D in several leading research organizations, including Duke University Medical Center and the Chinese Academy of Sciences. Jimmy received a Ph.D. in Biochemistry from North Carolina State University. He also holds an M.B.A. from Darden Business School, University of Virginia and a B.S. degree in Biology from Wuhan University.



Keyong Zou, PhD
Co-founder and CEO of Boston Open Labs LLC

Keyong Zou is a co-founder and CEO of Boston Open Labs LLC, a Cambridge, MA company providing high quality oligonucleotides and peptides to its customers. The company also offers break-through technologies and research options to help advance scientific research and drug R&D.

Keyong Zou received his Ph.D in Genetics from Texas A&M University in the lab of Professor Hagan Bayley. His thesis work focused on caging Tyr or Ser/Thr kinase at critical phosphorylation site with photo sensitive chemicals in order to control kinase activity by light. Keyong was a postdoctoral fellow with Dr. Jack Szostak in the Dept of Molecular Biology, Massachusetts General Hospital and Howard Hughes Medical Institute. There, his research was organic synthesis of TNA, a four carbon threose analog of DNA, and *in vitro* selection system of fully unnatural nucleic acids (aptamers).

2013 Harvard Chinese Life Science Research Award

Dr. Le Cong (Harvard Medical School)
Dr. Wenxian Fu (Harvard Medical School)
Dr. Xiaodong Jiang (Harvard Medical School)
Dr. Dong Kong (Beth Israel Deaconess Medical Center)
Dr. Jixi Li (Children's Hospital)
Dr. Xiaoyun Liao (Dana-Farber Cancer Institute)
Dr. Qibin Qi (Harvard School of Public Health)
Dr. Xu Tan (Brigham and Women's Hospital)
Dr. Jing Wang (Brigham and Women's Hospital)
Dr. Chuan Wu (Brigham and Women's Hospital)
Dr. Zeyu Xiao (Brigham and Women's Hospital)
Dr. Yufei Xu (Brigham and Women's Hospital)
Dr. Xinjun Zhang (Children's Hospital)
Dr. Xuehong Zhang (Brigham and Women's Hospital)

Sponsors

Diamond Sponsors



Biocytogen Co. Ltd. <http://www.biocytogen.com>

Developing Novel Gene-Targeted Models to Advance Life Science Research



Life Technologies, ABI brand
www.lifetechnologies.com

Integrated Systems for genetic Analysis

Golden Sponsors



GENEWIZ Inc www.genewiz.com

Top trusted genomics service provider since 1999



BIOSS www.biossusa.com

Reliable Antibody Producer



Boston Open Labs <http://bolresearch.com>

Provide oligonucleotide and peptide synthesis



Abmart www.ab-mart.com

Custom Monoclonal Antibody